Compugen

Historical price data

Compugen is a computational discovery-driven biotech focused on identifying and developing first-in-class cancer immunotherapies. Its core asset is the proprietary, AI/ML-powered Unigen™ platform, which integrates multi-omics data to predict novel immune checkpoints and therapeutic targets. The company has successfully translated its computational predictions into a clinical pipeline, with multiple programs in Phase 1/2 development. Its strategy is to advance these assets independently or through strategic partnerships to address significant unmet needs in oncology.

The Unigen™ platform is an AI/ML-powered computational discovery engine that integrates multi-omics data to systematically predict novel immune checkpoints and therapeutic targets in immuno-oncology, operating as a continuous learning system.

Competes with large pharma developing next-gen IO combinations and a growing field of biotechs targeting the myeloid compartment. Differentiates through its computationally-derived novel targets (e.g., PVRIG), first-mover advantage in developing them, and its proprietary, validated AI/ML discovery platform.